{"name":"Illinois Retina Associates","slug":"illinois-retina-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ranibizumab plus Photodynamic therapy","genericName":"Ranibizumab plus Photodynamic therapy","slug":"ranibizumab-plus-photodynamic-therapy","indication":"Wet age-related macular degeneration (AMD)","status":"marketed"}]}],"pipeline":[{"name":"Ranibizumab plus Photodynamic therapy","genericName":"Ranibizumab plus Photodynamic therapy","slug":"ranibizumab-plus-photodynamic-therapy","phase":"marketed","mechanism":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.","indications":["Wet age-related macular degeneration (AMD)","Choroidal neovascularization secondary to pathologic myopia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOa1NuMUpEUjJxY3NDOU8xVzkzejBlWGpCbm1aeWFidzRMeWpfMTJLc2NSeDhtczBhME9oc3M5WUJ1ZU96YUVlLXIzM19WVllEWTloSWR2d2FEelA3aUJ4Sy1CNWJQc1R5X051RDhoSkpwWjF2MTl3Y1R1U3I3QXo0NjAzTlluNzVIeVg2R0dDOEszU29tWV9Jb3NzaUlQQ3JmbllHdWpGb28taUctUmFKZmNXZVVqdm95d3lYU25fYTZjajJrU05QaEgwUnZ0R3hRTnJzWEVB?oc=5","date":"2025-10-19","type":"trial","source":"Modern Retina","summary":"EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME - Modern Retina","headline":"EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxON01RZkl1S21WYUZpTXdkVm5JdkxFYkpoS1RtU2tpMmVkaWQzUXNjSjBrV1BreXg1YXU1Y1VYZnVUUjFoUlZycmdWdE04S0UyakJUb09UT0MxWkd6am14ck9LWnk1ZDdkdjdraTlIVWlVSkdhRWpSZ1lCRjVvREI3Vko1Zjd0WG5hWTRjQk5NTWhKcUlROGV1b1JVa2Utck42VG9UbUMzTlZnMWVOdC1EYk1EMzE1c0d0cXNKTWNlN0RFRnVyQzFYXzIyWTFQUFNGTUJYZnRFeVV2ZGNHWVhBcmJlempmNVZ1VHN1T1hkYnl5bHdkTWNXWmVGck02MzNQLTdYUU9YMTZkMzg?oc=5","date":"2025-04-10","type":"trial","source":"PR Newswire","summary":"Pykus Therapeutics Completes Trial Enrollment for PYK-2101, a Novel Retinal Sealant for the Treatment for Retinal Detachment - PR Newswire","headline":"Pykus Therapeutics Completes Trial Enrollment for PYK-2101, a Novel Retinal Sealant for the Treatment for Retinal Detach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE40VmRsTlJFV2FHVWJCSXk5eHN2MFZGZkhNMWMzZERINDU0eEdfY0pwQWxQZkxxN3NNSEhjeGJSbzNEd3dtUWpkd29mLW5Ba2pjSktMZTRPOF80Z25UVEZ3?oc=5","date":"2024-08-26","type":"trial","source":"Nature","summary":"Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of Indi","headline":"Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study G","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB0RXRadEdJcjBERi1SLXd4bnVEWkpHc2ZpYllaT3pUSTBvVmVzeENleHVaczV6Vkd3cnVqdlV4eDhkRVVOQUw2ZE5HREtqWEVvd3FJTzRiZzNlQnZJclFZ?oc=5","date":"2024-04-15","type":"pipeline","source":"Nature","summary":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy - Nature","headline":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQNjJLalRRRDNqRzJNV2ZHOUhRRE5yaXFaMXFIUVNIVWtNd1hBOG9vVUNhd1lrQjlLVkN3Z21xNmFOdl9VMldtdXJtUDY2NGhERk1mTkhEeW5YZERiMk9BS2VFdXhyRDFlTm9YTTZNSEFxLXk1WFRqNEhSNWhPQXJzWGo4aGRzd3hzVlBxS3JMajFPMU01Q2NDOVBkNFhwMjlhTXVfZUJ3?oc=5","date":"2024-01-19","type":"pipeline","source":"Eyes On Eyecare","summary":"iuvo BioSciences purchases Promedica International - Eyes On Eyecare","headline":"iuvo BioSciences purchases Promedica International","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOYWs3ZHhLb3ota2dLZmNKNUxPMnF1RER2WWQzbGYzSDN4VDNvZVRSU0R0THRQNHZyYWRuZWNWSEtHc0tHc1BkZGFNbEg1bXBPNTJvSkI0RmI1RE5YMUQ5RVdsQmV5RDhQbmRyTDNqWUhTMFRsd3hRZnBOcmhST2FPb3U2dHdjVEJZVjBkUm14Sy0wbkhDUnFPanlTM3h3T2xwV21oMVlxYm9BWFB5VE9jQ3B4MnFFUENIQzcweDhEWkhNOS1tUW5VbTdqeWM2QUE?oc=5","date":"2023-12-01","type":"pipeline","source":"REJournals","summary":"Cushman & Wakefield represents Hollister Inc. in $11 million sale of Hollister Grove MOB portfolio in Libertyville - REJournals","headline":"Cushman & Wakefield represents Hollister Inc. in $11 million sale of Hollister Grove MOB portfolio in Libertyville","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}